CytomX Therapeutics CTMX Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's pre-tax income?
- CytomX Therapeutics (CTMX) reported pre-tax income of -$18.19M in Q1 2026.
- How has CytomX Therapeutics's pre-tax income changed year-over-year?
- CytomX Therapeutics's pre-tax income decreased by 177.1% year-over-year, from $23.59M to -$18.19M.
- What is the long-term trend for CytomX Therapeutics's pre-tax income?
- Over 4 years (2021 to 2025), CytomX Therapeutics's pre-tax income has grown at a -38.0% compound annual growth rate (CAGR), from -$115.87M to -$17.13M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.